Eli Lilly (LLY) and EVA Pharma said Tuesday the Egyptian Drug Authority approved the companies' collaboratively produced insulin glargine injection, allowing the release of locally manufactured insulin in Egypt.
This is the first regulatory approval for EVA Pharma's insulin drug products, according to the companies.
Lilly has been supplying EVA Pharma with its active ingredient for insulin under a collaboration to provide insulin for people with type 1 and type 2 diabetes living in low- to middle-income countries, the companies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments